Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22163628 | 0.90 | HTR2C (0.57) | NPC1RAB9APOLBALDH1A1EPHX2 | |
| SCHEMBL30002274 | 0.86 | SLC6A5 (0.61) | SLC6A5 | |
| SCHEMBL30002129 | 0.83 | MAPK8 (0.52) | NPC1RAB9APOLBALDH1A1SLC13A5 | |
| SCHEMBL30002330 | 0.83 | MAOB (0.53) | — | |
| SCHEMBL13745754 | 0.82 | ALDH1A1 (0.62) | POLBALDH1A1SLC13A5EPHX2KMT2A | |
| SCHEMBL30002029 | 0.80 | MEN1 (0.54) | SLC6A5KMT2A | |
| SCHEMBL29288204 | 0.80 | NPC1 (0.52) | NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL13746190 | 0.78 | MAPT (0.61) | POLBALDH1A1KMT2A | |
| SCHEMBL27370874 | 0.77 | NPSR1 (0.64) | POLBALDH1A1EPHX2KMT2A | |
| SCHEMBL13745506 | 0.75 | ALDH1A1 (0.70) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | AMTIXBIO CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| EP-4349329-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | Amtixbio Co., Ltd. (KR) | 2024-04-10 | — | — | EP | claimed |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | AMTIXBIO CO., LTD. (KR) | 2025-06-26 | — | — | US | disclosed |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-4349329-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | Amtixbio Co., Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| CN-117677382-A | Benzyloxy benzylamino amino acid derivatives that modulate TSLP/TSLPR signaling | 阿米蒂比奥有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110325509-B | Functional derivative compounds of alanine and proline amino acids and pharmaceutical compositions containing the same | 阿米蒂比奥有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116836083-A | Functional derivative compounds of alanine and proline amino acids and pharmaceutical compositions containing the same | 阿米蒂比奥有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022255801-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | (주)앰틱스바이오 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | BCAT2, BCAT1, DAO | SLC6A5 502/4885NPC1 1429/4885RAB9A 2386/4885 |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PEPD, BCAT1, ANPEP | SLC6A5 443/4885NPC1 653/4885RAB9A 2261/4885 |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | ERG28, BCAT2, AADAT | SLC6A5 776/4885NPC1 646/4885RAB9A 2489/4885 |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | PEPD, PREP, ANPEP | SLC6A5 521/4885NPC1 717/4885RAB9A 3402/4885 |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | TSLP, IL2RA, TRPC7 | SLC6A5 1295/4885NPC1 3483/4885RAB9A 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.